Continuous Glucose Monitoring to Detect Postpartum Dysglycemia in Patients With Gestational Diabetes
Launched by UNIVERSITY OF CHICAGO · Jun 13, 2025
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how well a device called a continuous glucose monitor (CGM) can detect blood sugar problems in women who had gestational diabetes during pregnancy. Gestational diabetes is a type of high blood sugar that some women develop only during pregnancy. The study will look at how the CGM works after delivery to predict if a woman’s blood sugar is still abnormal when tested with a standard glucose test 4 to 12 weeks after having the baby.
Women who are 18 years or older, have recently given birth to a live baby (including twins or more), and were diagnosed with gestational diabetes during pregnancy may be eligible to join. Women with no history of type 1 or type 2 diabetes before pregnancy can participate, even if they had gestational diabetes in a previous pregnancy. If they join the study, participants will wear the CGM device after delivery to monitor their blood sugar levels continuously. This study is not yet recruiting, but it aims to help doctors find better ways to check blood sugar in new mothers who had gestational diabetes, so they can get the care they need early on.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • 1. Age greater than or equal to 18
- • 2. Completed pregnancy with delivery of a live born infant(s). Pregnancies with multiple gestations will be included
- • 3. No prior history of type 1 or type 2 diabetes
- • \* Patients with a history of gestational diabetes (GDM) in a prior pregnancy will be eligible for inclusion.
- • 4. GDM diagnosis by standard screening at 24-28 weeks
- • 2 hour 75g oral glucose tolerance test (OGTT); one abnormal value required for diagnosis
- • Fasting glucose 92
- • 1 hour 180
- • 2 hour 153
- • 3 hour 100g OGTT - two abnormal values required for diagnosis
- • Fasting glucose - 95
- • 1 hour 180
- • 2 hour 155
- • 3 hour 140
- • There are no exclusion criteria for this study. Eligibility will be based on inclusion criteria.
About University Of Chicago
The University of Chicago is a prestigious research institution renowned for its commitment to advancing medical science through innovative clinical trials. With a robust infrastructure that supports multidisciplinary collaboration, the University actively engages in cutting-edge research across various therapeutic areas. Its dedicated team of experienced investigators and state-of-the-art facilities enable the University of Chicago to conduct rigorous clinical studies aimed at improving patient outcomes and translating scientific discoveries into tangible healthcare solutions. The institution prioritizes ethical standards and patient safety, ensuring that all trials adhere to the highest regulatory guidelines and best practices in clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Laura Dickens, MD
Principal Investigator
University of Chicago
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported